Implementation and utilization of genetic testing in personalized medicine

References

• ShuldinerARRellingMVPetersonJFPharmacogenomics Research Network Translational Pharmacogenetics Program GroupThe Pharmacogenomics Research Network Translational Pharmacogenetics Program: overcoming challenges of real-world implementationClin Pharmacol Ther201394220721023588301
   PubMed Web of Science ®Google Scholar
• RellingMVKleinTECPIC: Clinical Pharmacogenetics Implementation Consortium of the Pharmacogenomics Research NetworkClin Pharmacol Ther201189346446721270786
   PubMed Web of Science ®Google Scholar
• RobertsJDWellsGALe MayMRPoint-of-care genetic testing for personalisation of antiplatelet treatment (RAPID GENE): a prospective, randomised, proof-of-concept trialLancet201237998271705171122464343
   PubMed Web of Science ®Google Scholar
• GoldspielBRFlegelWADiPatrizioGIntegrating pharmacogenetic information and clinical decision support into the electronic health recordJ Am Med Inform Assoc201421352252824302286
   PubMed Web of Science ®Google Scholar
• SandersonSZimmernRKroeseMHigginsJPatchCEmeryJHow can the evaluation of genetic tests be enhanced? Lessons learned from the ACCE framework and evaluating genetic tests in the United KingdomGenet Med20057749550016170241
   PubMed Web of Science ®Google Scholar
• KochWHTechnology platforms for pharmacogenomic diagnostic assaysNat Rev Drug Discov20043974976115340385
   PubMed Web of Science ®Google Scholar
• KingCRPorche-SorbetRMGageBFPerformance of commercial platforms for rapid genotyping of polymorphisms affecting warfarin doseAm J Clin Pathol2008129687688318480003
   PubMed Web of Science ®Google Scholar
• PhillipsEMallalSSuccessful translation of pharmacogenetics into the clinic: the abacavir exampleMol Diagn Ther20091311919351209
   PubMed Web of Science ®Google Scholar
• BurtTDhillonSPharmacogenomics in early-phase clinical developmentPharmacogenomics20131491085109723837482
   PubMed Web of Science ®Google Scholar
• MeyerUAPharmacogenetics – five decades of therapeutic lessons from genetic diversityNat Rev Genet20045966967615372089
   PubMed Web of Science ®Google Scholar
• DeanCEPersonalized medicine: boon or budget-buster?Ann Pharmacother200943595896219417115
   PubMed Web of Science ®Google Scholar
• WelterDMacArthurJMoralesJThe NHGRI GWAS Catalog, a curated resource of SNP-trait associationsNucleic Acids Res201442Database issueD1001D100624316577
   PubMed Web of Science ®Google Scholar
• AbrahamsEGinsburgGSSilverMThe Personalized Medicine Coalition: goals and strategiesAm J Pharmacogenomics20055634535516336000
   PubMedGoogle Scholar
• EdwardsAORitterR3rdAbelKJManningAPanhuysenCFarrerLAComplement factor H polymorphism and age-related macular degenerationScience2005308572042142415761121
   PubMed Web of Science ®Google Scholar
• RatnapriyaRChewEYAge-related macular degeneration-clinical review and genetics updateClin Genet201384216016623713713
   PubMed Web of Science ®Google Scholar
• AwhCCLaneAMHawkenSZankeBKimIKCFH and ARMS2 genetic polymorphisms predict response to antioxidants and zinc in patients with age-related macular degenerationOphthalmology2013120112317232323972322
   PubMed Web of Science ®Google Scholar
• SingalDPBlajchmanMAHistocompatibility (HL-A) antigens, lymphocytotoxic antibodies and tissue antibodies in patients with diabetes mellitusDiabetes19732264294324541338
   PubMed Web of Science ®Google Scholar
• NobleJAValdesAMCookMKlitzWThomsonGErlichHAThe role of HLA class II genes in insulin-dependent diabetes mellitus: molecular analysis of 180 Caucasian, multiplex familiesAm J Hum Genet1996595113411488900244
   PubMed Web of Science ®Google Scholar
• BarrettJCClaytonDGConcannonPType 1 Diabetes Genetics ConsortiumGenome-wide association study and meta-analysis find that over 40 loci affect risk of type 1 diabetesNat Genet200941670370719430480
   PubMed Web of Science ®Google Scholar
• ConcannonPRichSSNepomGTGenetics of type 1A diabetesN Engl J Med2009360161646165419369670
   PubMed Web of Science ®Google Scholar
• ClaytonDGPrediction and interaction in complex disease genetics: experience in type 1 diabetesPLoS Genet200957e100054019584936
   PubMed Web of Science ®Google Scholar
• ChoJHGregersenPKGenomics and the multifactorial nature of human autoimmune diseaseN Engl J Med2011365171612162322029983
   PubMed Web of Science ®Google Scholar
• ManolioTAGenomewide association studies and assessment of the risk of diseaseN Engl J Med2010363216617620647212
   PubMed Web of Science ®Google Scholar
• ManolioTACollinsFSCoxNJFinding the missing heritability of complex diseasesNature2009461726574775319812666
   PubMed Web of Science ®Google Scholar
• van der SijdeMRNgAFuJSystems genetics: From GWAS to disease pathwaysBiochim Biophys Acta Epub522014
   Web of Science ®Google Scholar
• D’AgostinoRBSrVasanRSPencinaMJGeneral cardiovascular risk profile for use in primary care: the Framingham Heart StudyCirculation2008117674375318212285
   PubMed Web of Science ®Google Scholar
• EastonDFBishopDTFordDCrockfordGPGenetic linkage analysis in familial breast and ovarian cancer: results from 214 families. The Breast Cancer Linkage ConsortiumAm J Hum Genet19935246787018460634
   PubMed Web of Science ®Google Scholar
• WoosterRNeuhausenSLMangionJLocalization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12–13Science19942655181208820908091231
   PubMed Web of Science ®Google Scholar
• ACOG Committee on Practice BulletinsHereditary breast and ovarian cancer syndromeGynecol Oncol2009113161119309638
   PubMed Web of Science ®Google Scholar
• SeddonJMReynoldsRMallerJFagernessJADalyMJRosnerBPrediction model for prevalence and incidence of advanced age-related macular degeneration based on genetic, demographic, and environmental variablesInvest Ophthalmol Vis Sci20095052044205319117936
   PubMed Web of Science ®Google Scholar
• DvoskinRGPPC releases updated list of DTC genetic testing companies [press release]Washington, DCThe Genetics and Public Policy Center8112011 Available from: http://www.dnapolicy.org/news.release.php?action=detail&pressrelease_id=145Accessed March 30, 2014
   Google Scholar
• KalfRRMihaescuRKunduSde KnijffPGreenRCJanssensACVariations in predicted risks in personal genome testing for common complex diseasesGenet Med2014161859123807614
   PubMed Web of Science ®Google Scholar
• NgPCMurraySSLevySVenterJCAn agenda for personalized medicineNature2009461726572472619812653
   PubMed Web of Science ®Google Scholar
• ChuaEWKennedyMACurrent State and Future Prospects of Direct-to-Consumer PharmacogeneticsFront Pharmacol2012315222934000
   PubMed Web of Science ®Google Scholar
• VogelFModerne Problem der Humangenetik. [Modern problems of human genetics]Ergeb Inn Med Kinderheilkd19591252125 German
   Google Scholar
• MahgoubAIdleJRDringLGLancasterRSmithRLPolymorphic hydroxylation of Debrisoquine in manLancet19772803858458671400
   PubMed Web of Science ®Google Scholar
• OwenRPSangkuhlKKleinTEAltmanRBCytochrome P450 2D6Pharmacogenet Genomics200919755956219512959
   PubMed Web of Science ®Google Scholar
• SimSCIngelman-SundbergMThe Human Cytochrome P450 (CYP) Allele Nomenclature website: a peer-reviewed database of CYP variants and their associated effectsHum Genomics20104427828120511141
   PubMedGoogle Scholar
• Van BoovenDMarshSMcLeodHCytochrome P450 2C9-CYP2C9Pharmacogenet Genomics201020427728120150829
   PubMed Web of Science ®Google Scholar
• ScottSASangkuhlKShuldinerARPharmGKB summary: very important pharmacogene information for cytochrome P450, family 2, subfamily C, polypeptide 19Pharmacogenet Genomics201222215916522027650
   PubMed Web of Science ®Google Scholar
• AithalGPDayCPKestevenPJDalyAKAssociation of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complicationsLancet1999353915471771910073515
   PubMed Web of Science ®Google Scholar
• OwenRPGongLSagreiyaHKleinTEAltmanRBVKORC1 pharmacogenomics summaryPharmacogenet Genomics2010201064264419940803
   PubMed Web of Science ®Google Scholar
• LimdiNAWadeliusMCavallariLInternational Warfarin Pharmacogenetics ConsortiumWarfarin pharmacogenetics: a single VKORC1 polymorphism is predictive of dose across 3 racial groupsBlood2010115183827383420203262
   PubMed Web of Science ®Google Scholar
• KleinTEAltmanRBErikssonNInternational Warfarin Pharmacogenetics ConsortiumEstimation of the warfarin dose with clinical and pharmacogenetic dataN Engl J Med2009360875376419228618
   PubMed Web of Science ®Google Scholar
• FinkelmanBSGageBFJohnsonJABrensingerCMKimmelSEGenetic warfarin dosing: tables versus algorithmsJ Am Coll Cardiol201157561261821272753
   PubMed Web of Science ®Google Scholar
• PirmohamedMBurnsideGErikssonNEU-PACT GroupA randomized trial of genotype-guided dosing of warfarinN Engl J Med2013369242294230324251363
   PubMed Web of Science ®Google Scholar
• KimmelSEFrenchBKasnerSECOAG InvestigatorsA pharmacogenetic versus a clinical algorithm for warfarin dosingN Engl J Med2013369242283229324251361
   PubMed Web of Science ®Google Scholar
• ZinehIPacanowskiMWoodcockJPharmacogenetics and coumarin dosing – recalibrating expectationsN Engl J Med2013369242273227524328463
   PubMed Web of Science ®Google Scholar
• ShuldinerARO’ConnellJRBlidenKPAssociation of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapyJAMA2009302884985719706858
   PubMed Web of Science ®Google Scholar
• MegaJLSimonTColletJPReduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysisJAMA2010304161821183020978260
   PubMed Web of Science ®Google Scholar
• LeeAEzzeldinHFourieJDiasioRDihydropyrimidine dehydrogenase deficiency: impact of pharmacogenetics on 5-fluorouracil therapyClin Adv Hematol Oncol20042852753216163233
   PubMedGoogle Scholar
• WangLPelleymounterLWeinshilboumRVery important pharmacogene summary: thiopurine S-methyltransferasePharmacogenet Genomics201020640140520154640
   PubMed Web of Science ®Google Scholar
• BarbarinoJMHaidarCEKleinTEAltmanRBPharmGKB summary: very important pharmacogene information for UGT1A1Pharmacogenet Genomics201424317718324492252
   PubMed Web of Science ®Google Scholar
• LinkEParishSArmitageJSEARCH Collaborative GroupSLCO1B1 variants and statin-induced myopathy – a genomewide studyN Engl J Med2008359878979918650507
   PubMed Web of Science ®Google Scholar
• OshiroCMangraviteLKleinTAltmanRPharmGKB very important pharmacogene: SLCO1B1Pharmacogenet Genomics201020321121619952871
   PubMed Web of Science ®Google Scholar
• CrowleyJJSullivanPFMcLeodHLPharmacogenomic genome-wide association studies: lessons learned thus farPharmacogenomics200910216116319207016
   PubMed Web of Science ®Google Scholar
• Motsinger-ReifAAJorgensonERellingMVGenome-wide association studies in pharmacogenomics: successes and lessonsPharmacogenet Genomics201323838339420639796
   PubMed Web of Science ®Google Scholar
• DalyAKGenome-wide association studies in pharmacogenomicsNat Rev Genet201011424124620300088
   PubMed Web of Science ®Google Scholar
• GeDFellayJThompsonAJGenetic variation in IL28B predicts hepatitis C treatment-induced viral clearanceNature2009461726239940119684573
   PubMed Web of Science ®Google Scholar
• TreviñoLRShimasakiNYangWGermline genetic variation in an organic anion transporter polypeptide associated with methotrexate pharmacokinetics and clinical effectsJ Clin Oncol200927355972597819901119
   PubMed Web of Science ®Google Scholar
• TantisiraKGLasky-SuJHaradaMGenomewide association between GLCCI1 and response to glucocorticoid therapy in asthmaN Engl J Med2011365131173118321991891
   PubMed Web of Science ®Google Scholar
• CooperGMJohnsonJALangaeeTYA genome-wide scan for common genetic variants with a large influence on warfarin maintenance doseBlood200811241022102718535201
   PubMed Web of Science ®Google Scholar
• TakeuchiFMcGinnisRBourgeoisSA genome-wide association study confirms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dosePLoS Genet200953e100043319300499
   PubMed Web of Science ®Google Scholar
• DalyAKDonaldsonPTBhatnagarPDILIGEN StudyInternational SAE ConsortiumHLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillinNat Genet200941781681919483685
   PubMed Web of Science ®Google Scholar
• McCormackMAlfirevicABourgeoisSHLA-A*3101 and carbamazepine-induced hypersensitivity reactions in EuropeansN Engl J Med2011364121134114321428769
   PubMed Web of Science ®Google Scholar
• KalowWEthnic differences in drug metabolismClin Pharmacokinet1982753734006754206
   PubMed Web of Science ®Google Scholar
• KalowWBertilssonLInterethnic factors affecting drug responseAdv Drug Res199425153
   Google Scholar
• GeorgitsiMViennasEGkantounaVPopulation-specific documentation of pharmacogenomic markers and their allelic frequencies in FINDbasePharmacogenomics2011121495821174622
   PubMed Web of Science ®Google Scholar
• ScottSAPersonalizing medicine with clinical pharmacogeneticsGenet Med2011131298799522095251
   PubMed Web of Science ®Google Scholar
• Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working GroupRecommendations from the EGAPP Working Group: testing for cytochrome P450 polymorphisms in adults with nonpsychotic depression treated with selective serotonin reuptake inhibitorsGenet Med200791281982518091431
   PubMed Web of Science ®Google Scholar
• Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working GroupRecommendations from the EGAPP Working Group: can UGT1A1 genotyping reduce morbidity and mortality in patients with metastatic colorectal cancer treated with irinotecan?Genet Med2009111152019125128
   PubMed Web of Science ®Google Scholar
• SwenJJNijenhuisMde BoerAPharmacogenetics: from bench to byte – an update of guidelinesClin Pharmacol Ther201189566267321412232
   PubMed Web of Science ®Google Scholar
• BecquemontLAlfirevicAAmstutzUPractical recommendations for pharmacogenomics-based prescription: 2010 ESF-UB Conference on Pharmacogenetics and PharmacogenomicsPharmacogenomics201112111312421174626
   PubMed Web of Science ®Google Scholar
• TeutschSMBradleyLAPalomakiGEEGAPP Working GroupThe Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Initiative: methods of the EGAPP Working GroupGenet Med200911131418813139
   PubMed Web of Science ®Google Scholar
• WuAHGenotype and phenotype concordance for pharmacogenetic tests through proficiency survey testingArch Pathol Lab Med201313791232123623991737
   PubMed Web of Science ®Google Scholar
• PrattVMZehnbauerBWilsonJACharacterization of 107 genomic DNA reference materials for CYP2D6, CYP2C19, CYP2C9, VKORC1, and UGT1A1: a GeT-RM and Association for Molecular Pathology collaborative projectJ Mol Diagn201012683584620889555
   PubMed Web of Science ®Google Scholar
• DobsonMGGalvinPBartonDEEmerging technologies for point-of-care genetic testingExpert Rev Mol Diagn20077435937017620045
   PubMed Web of Science ®Google Scholar
• BuchanBWPetersonJFCogbillCHEvaluation of a microarray-based genotyping assay for the rapid detection of cytochrome P450 2C19 *2 and *3 polymorphisms from whole blood using nanoparticle probesAm J Clin Pathol2011136460460821917683
   PubMed Web of Science ®Google Scholar
• MallalSPhillipsECarosiGPREDICT-1 Study TeamHLA-B*5701 screening for hypersensitivity to abacavirN Engl J Med2008358656857918256392
   PubMed Web of Science ®Google Scholar
• ChenPLinJJLuCSTaiwan SJS ConsortiumCarbamazepine-induced toxic effects and HLA-B*1502 screening in TaiwanN Engl J Med2011364121126113321428768
   PubMed Web of Science ®Google Scholar
• LeskoLJSchmidtSClinical implementation of genetic testing in medicine: a US regulatory science perspectiveBr J Clin Pharmacol201477460661124286486
   PubMed Web of Science ®Google Scholar
• FeeroWGGreenEDGenomics education for health care professionals in the 21st centuryJAMA2011306998999021900139
   PubMed Web of Science ®Google Scholar
• OsheroffJATeichJMMiddletonBSteenEBWrightADetmerDEA roadmap for national action on clinical decision supportJ Am Med Inform Assoc200714214114517213487
   PubMed Web of Science ®Google Scholar
• CrewsKRCrossSJMcCormickJNDevelopment and implementation of a pharmacist-managed clinical pharmacogenetics serviceAm J Health Syst Pharm201168214315021200062
   PubMed Web of Science ®Google Scholar
• FernandezCASmithCYangWConcordance of DMET plus genotyping results with those of orthogonal genotyping methodsClin Pharmacol Ther201292336036522871999
   PubMed Web of Science ®Google Scholar
• HicksJKCrewsKRHoffmanJMA clinician-driven automated system for integration of pharmacogenetic interpretations into an electronic medical recordClin Pharmacol Ther201292556356622990750
   PubMed Web of Science ®Google Scholar
• PulleyJMDennyJCPetersonJFOperational implementation of prospective genotyping for personalized medicine: the design of the Vanderbilt PREDICT projectClin Pharmacol Ther2012921879522588608
   PubMed Web of Science ®Google Scholar
• JohnsonJAElseyARClare-SalzlerMJNesslDConlonMNelsonDRInstitutional profile: University of Florida and Shands Hospital Personalized Medicine Program: clinical implementation of pharmacogeneticsPharmacogenomics201314772372623651020
   PubMed Web of Science ®Google Scholar
• JohnsonJABurkleyBMLangaeeTYClare-SalzlerMJKleinTEAltmanRBImplementing personalized medicine: development of a cost-effective customized pharmacogenetics genotyping arrayClin Pharmacol Ther201292443743922910441
   PubMed Web of Science ®Google Scholar
• O’DonnellPHBushASpitzJThe 1200 patients project: creating a new medical model system for clinical implementation of pharmacogenomicsClin Pharmacol Ther201292444644922929923
   PubMed Web of Science ®Google Scholar
• RatainMJPersonalized medicine: building the GPS to take us thereClin Pharmacol Ther200781332132217339859
   PubMed Web of Science ®Google Scholar
• GottesmanOScottSAEllisSBThe CLIPMERGE PGx Program: clinical implementation of personalized medicine through electronic health records and genomics-pharmacogenomicsClin Pharmacol Ther201394221421723588317
   PubMed Web of Science ®Google Scholar
• OverbyCLErwinALAbul-HusnNSPhysician Attitudes toward Adopting Genome-Guided Prescribing through Clinical Decision SupportJ Pers Med2014413549
   PubMedGoogle Scholar
• KellerMAGordonESStackCBCoriell Personalized Medicine Collaborative®: a prospective study of the utility of personalized medicinePer Med201073301317
   PubMed Web of Science ®Google Scholar
• StackCBGharaniNGordonESSchmidlenTChristmanMFKellerMAGenetic risk estimation in the Coriell Personalized Medicine CollaborativeGenet Med201113213113921233721
   PubMed Web of Science ®Google Scholar
• GharaniNKellerMAStackCBThe Coriell personalized medicine collaborative pharmacogenomics appraisal, evidence scoring and interpretation systemGenome Med20135109324134832
   PubMed Web of Science ®Google Scholar
• LermanCCroyleRTTercyakKPHamannHGenetic testing: psychological aspects and implicationsJ Consult Clin Psychol200270378479712090383
   PubMed Web of Science ®Google Scholar
• WardRLHicksSHawkinsNJPopulation-based molecular screening for Lynch syndrome: implications for personalized medicineJ Clin Oncol201331202554256223733757
   PubMed Web of Science ®Google Scholar
• MeiserBPsychological impact of genetic testing for cancer susceptibility: an update of the literaturePsychooncology200514121060107415937976
   PubMed Web of Science ®Google Scholar
• CreightonSAlmqvistEWMacGregorDPredictive, pre-natal and diagnostic genetic testing for Huntington’s disease: the experience in Canada from 1987 to 2000Clin Genet200363646247512786753
   PubMed Web of Science ®Google Scholar
• MorrisonPJHarding-LesterSBradleyAUptake of Huntington disease predictive testing in a complete populationClin Genet201180328128620880124
   PubMed Web of Science ®Google Scholar
• RobertsJSBarberMBrownTMWho seeks genetic susceptibility testing for Alzheimer’s disease? Findings from a multisite, randomized clinical trialGenet Med20046419720315266207
   PubMed Web of Science ®Google Scholar
• FosterMWMulvihillJJSharpRREvaluating the utility of personal genomic informationGenet Med200911857057419478683
   PubMed Web of Science ®Google Scholar
• RobertsJSOstergrenJDirect-to-Consumer Genetic Testing and Personal Genomics Services: A Review of Recent Empirical StudiesCurr Genet Med Rep20131318220024058877
   PubMedGoogle Scholar
• BlossCSSchorkNJTopolEJEffect of direct-to-consumer genomewide profiling to assess disease riskN Engl J Med2011364652453421226570
   PubMed Web of Science ®Google Scholar
• GiovanniMAFickieMRLehmannLSHealth-care referrals from direct-to-consumer genetic testingGenet Test Mol Biomarkers201014681781920979566
   PubMed Web of Science ®Google Scholar
• KaufmanDJBollingerJMDvoskinRLScottJARisky business: risk perception and the use of medical services among customers of DTC personal genetic testingJ Genet Couns201221341342222278220
   PubMed Web of Science ®Google Scholar
• HagaSBO’DanielJMTindallGMLipkusIRAgansRSurvey of US public attitudes toward pharmacogenetic testingPharmacogenomics J201212319720421321582
   PubMed Web of Science ®Google Scholar
• SandersonSCWardleJAssociations between anticipated reactions to genetic test results and interest in genetic testing: will self-selection reduce the potential for harm?Genet Test2008121596618318647
   PubMedGoogle Scholar
• HagaSBTindallGO’DanielJMPublic perspectives about pharmacogenetic testing and managing ancillary findingsGenet Test Mol Biomarkers201216319319722047505
   PubMed Web of Science ®Google Scholar
• SandersonSCHumphriesSEHubbartCHughesEJarvisMJWardleJPsychological and behavioural impact of genetic testing smokers for lung cancer risk: a phase II exploratory trialJ Health Psychol200813448149418420756
   PubMed Web of Science ®Google Scholar
• MarteauTMFrenchDPGriffinSJEffects of communicating DNA-based disease risk estimates on risk-reducing behaviours [review]Cochrane Database Syst Rev201010CD00727520927756
   PubMed Web of Science ®Google Scholar
• VernarelliJARobertsJSHirakiSChenCACupplesLAGreenRCEffect of Alzheimer disease genetic risk disclosure on dietary supplement useAm J Clin Nutr20109151402140720219963
   PubMed Web of Science ®Google Scholar
• ZickCDMathewsCJRobertsJSCook-DeeganRPokorskiRJGreenRCGenetic testing for Alzheimer’s disease and its impact on insurance purchasing behaviorHealth Aff (Millwood)200524248349015757934
   PubMed Web of Science ®Google Scholar
• HagaSBLaPointeNMThe potential impact of pharmacogenetic testing on medication adherencePharmacogenomics J201313648148323999596
   PubMed Web of Science ®Google Scholar
• SchwartzSMSchwartzHTHorvathSSchadtELeeSIA systematic approach to multifactorial cardiovascular disease: causal analysisArterioscler Thromb Vasc Biol201232122821283523087359
   PubMed Web of Science ®Google Scholar
• HayesDFMarkusHSLeslieRDTopolEJPersonalized medicine: risk prediction, targeted therapies and mobile health technologyBMC Med2014123724580858
   PubMed Web of Science ®Google Scholar
• ClancyJPJohnsonSGYeeSWClinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for ivacaftor therapy in the context of CFTR genotypeClin Pharmacol Ther201495659259724598717
   PubMed Web of Science ®Google Scholar
• FlockhartDAO’KaneDWilliamsMSACMG Working Group on Pharmacogenetic Testing of CYP2C9, VKORC1 Alleles for Warfarin UsePharmacogenetic testing of CYP2C9 and VKORC1 alleles for warfarinGenet Med200810213915018281922
   PubMed Web of Science ®Google Scholar
• JohnsonJAGongLWhirl-CarrilloMClinical Pharmacogenetics Implementation ConsortiumClinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and VKORC1 genotypes and warfarin dosingClin Pharmacol Ther201190462562921900891
   PubMed Web of Science ®Google Scholar
• ScottSASangkuhlKGardnerEEClinical Pharmacogenetics Implementation ConsortiumClinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450-2C19 (CYP2C19) genotype and clopidogrel therapyClin Pharmacol Ther201190232833221716271
   PubMed Web of Science ®Google Scholar
• ScottSASangkuhlKSteinCMClinical Pharmacogenetics Implementation ConsortiumClinical Pharmacogenetics Implementation Consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 updateClin Pharmacol Ther201394331732323698643
   PubMed Web of Science ®Google Scholar
• HolmesDRDehmerGJKaulSLeiferDO’GaraPTSteinCMACCF/AHA clopidogrel clinical alert: approaches to the FDA “boxed warning”: a report of the American College of Cardiology Foundation Task Force on clinical expert consensus documents and the American Heart Association endorsed by the Society for Cardiovascular Angiography and Interventions and the Society of Thoracic SurgeonsJ Am Coll Cardiol201056432134120633831
   PubMed Web of Science ®Google Scholar
• HicksJKSwenJJThornCFClinical Pharmacogenetics Implementation ConsortiumClinical Pharmacogenetics Implementation Consortium guideline for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressantsClin Pharmacol Ther201393540240823486447
   PubMed Web of Science ®Google Scholar
• CrewsKRGaedigkADunnenbergerHMClinical Pharmacogenetics Implementation ConsortiumClinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for codeine therapy in the context of cytochrome P450 2D6 (CYP2D6) genotypeClin Pharmacol Ther201291232132622205192
   PubMed Web of Science ®Google Scholar
• LyonEGastier FosterJPalomakiGEworking group of the Molecular Genetics Subcommittee on behalf of the American College of Medical Genetics and Genomics ACMG) Laboratory Quality Assurance CommitteeLaboratory testing of CYP2D6 alleles in relation to tamoxifen therapyGenet Med20121412990100022955113
   PubMed Web of Science ®Google Scholar
• CaudleKEThornCFKleinTEClinical Pharmacogenetics Implementation Consortium guidelines for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosingClin Pharmacol Ther201394664064523988873
   PubMed Web of Science ®Google Scholar
• MartinMAKleinTEDongBJPirmohamedMHaasDWKroetzDLClinical Pharmacogenetics Implementation ConsortiumClinical pharmacogenetics implementation consortium guidelines for HLA-B genotype and abacavir dosingClin Pharmacol Ther201291473473822378157
   PubMed Web of Science ®Google Scholar
• HershfieldMSCallaghanJTTassaneeyakulWClinical Pharmacogenetics Implementation Consortium guidelines for human leukocyte antigen-B genotype and allopurinol dosingClin Pharmacol Ther201393215315823232549
   PubMed Web of Science ®Google Scholar
• LeckbandSGKelsoeJRDunnenbergerHMClinical Pharmacogenetics Implementation ConsortiumClinical Pharmacogenetics Implementation Consortium guidelines for HLA-B genotype and carbamazepine dosingClin Pharmacol Ther201394332432823695185
   PubMed Web of Science ®Google Scholar
• MuirAJGongLJohnsonSGClinical Pharmacogenetics Implementation Consortium (CPIC)Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for IFNL3 (IL28B) genotype and PEG interferon-α-based regimensClin Pharmacol Ther201495214114624096968
   PubMed Web of Science ®Google Scholar
• WilkeRARamseyLBJohnsonSGClinical Pharmacogenomics Implementation Consortium (CPIC)The clinical pharmacogenomics implementation consortium: CPIC guideline for SLCO1B1 and simvastatin-induced myopathyClin Pharmacol Ther201292111211722617227
   PubMed Web of Science ®Google Scholar
• RellingMVGardnerEESandbornWJClinical Pharmacogenetics Implementation ConsortiumClinical Pharmacogenetics Implementation Consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosingClin Pharmacol Ther201189338739121270794
   PubMed Web of Science ®Google Scholar
• RellingMVGardnerEESandbornWJClinical pharmacogenetics implementation consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing: 2013 updateClin Pharmacol Ther201393432432523422873
   PubMed Web of Science ®Google Scholar
• RaimundoSToscanoCKleinKA novel intronic mutation, 2988G>A, with high predictivity for impaired function of cytochrome P450 2D6 in white subjectsClin Pharmacol Ther200476212813815289790
   PubMed Web of Science ®Google Scholar